Abivax SA

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

ABIVAX Société Anonyme (OTC:AAVXF) Q4 2023 Earnings Conference Call April 8, 2024 8:30 AM ET Company Participants Patrick Malloy - SVP, IR Marc de Garidel - CEO Sheldon Sloan - Chief Medical Officer Didier Scherrer - Chief Scientific Officer Conference Call Participants Thomas Smith - Leerink Partners Vikram Purohit - Morgan Stanley Julian Harrison - BTIG Operator Ladies and gentlemen, thank you for standing by. Welcome to ABIVAX Conference Call to discuss 2023 Financial Results and Business Update.

ABIVAX Société Anonyme (AAVXF) Q4 2023 Earnings Call Transcript

Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and EUR 223.3M initial public offering on the Nasdaq Global Market Sufficient funds to finance operations into Q4 2025, including through the announcement of top-line data from the Phase 3 ABTECT induction trials of obefazimod in ulcerative colitis (UC) Implementation of U.S. and European operational infrastructure to progress the Company's ongoing clinical and preclinical programs PARIS, France, April 2, 2024, 8:30 a.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced its 2023 annual financial results, as of December 31, 2023, and provided an update on the progress of its development programs.

Abivax reports 2023 financial results and operational update

PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that four scientific abstracts on its lead drug candidate, obefazimod for the treatment of moderately to severely active ulcerative colitis (UC), will be presented during the 19th Congress of the European Crohn's and Colitis Organisation (ECCO) on February 21-24, 2024, in Stockholm, Sweden. "We are delighted that all four submitted abstracts have been accepted for presentations at ECCO.

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)

LONDON--(BUSINESS WIRE)--Citi, acting through Citibank N.A., has been appointed by Abivax SA (“Abivax”), to act as depositary bank for its initial public offering (the “IPO”) of Abivax's American Depositary Shares (“ADSs” or “ADRs”) representing its ordinary shares. Abivax's ADSs trade on the Nasdaq Global Market under the ticker symbol “ABVX”. The company's underlying ordinary shares are listed on Euronext Paris under the symbol “ABVX”. Each ADS represents one ordinary share of the company. Co.

Citi Appointed as Depositary Bank for Abivax SA's ADR Program

PARIS, FRANCE / ACCESSWIRE / October 24, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced the closing of its previously announced initial public offering on the Nasdaq Global Market by way of a capital increase of 20,325,500 new ordinary shares (the " New Shares "), consisting of a public offering of 18,699,460 ordinary shares in the form of American Depositary Shares (" ADSs "), each representing the right to receive one ordinary share, in the United States (the " U.S. Offering ") and a concurrent offering of 1,626,040 ordinary shares in certain jurisdictions outside of the United States to certain investors (the " European Private Placement " and together with the U.S. Offering, the " Global Offering "). The offering price was set at $11.60 per ADS in the U.S. Offering and a corresponding offering price of €10.9864 per ordinary share in the European Private Placement.

Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market

Hamilton Insurance Group Ltd

J-Long Group Ltd

Mach Natural Resources LP

iShares MSCI Global Impact ETF

Northann Corp

Webuy Global Ltd

Both the calendar and the pipeline saw some movement this past week. Two large IPOs launched, one of which also priced, and two sizable deals submitted new filings. Eight IPOs submitted initial filings, led by three sizable names. Mach Natural Resources is currently the only IPO scheduled for the week ahead, although some small issuers may join the calendar late.

U.S. IPO Weekly Recap: Big Launches And New Filings Keep The IPO Market Moving

PARIS, FRANCE / ACCESSWIRE / October 20, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on Euronext in Paris ("Euronext Paris") as from 4:20 p.m. CEST.

Abivax Announces Trading Resumption of its Ordinary Shares on Euronext Paris

PARIS, FRANCE / ACCESSWIRE / October 20, 2023 / Abivax SA (Euronext Paris:FR0012333284:ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today the pricing of its initial public offering on the Nasdaq Global Market by way of a capital increase of 20,325,500 new ordinary shares (the " New Shares "), consisting of a public offering of 18,699,460 ordinary shares in the form of American Depositary Shares (" ADSs "), each representing the right to receive one ordinary share, in the United States (the " U.S. Offering ") and a concurrent offering of 1,626,040 ordinary shares in certain jurisdictions outside of the United States to certain investors (the " European Private Placement " and together with the U.S. Offering, the " Global Offering "). The offering price was set at $11.60 per ADS in the U.S. Offering and a corresponding offering price of €10.9864 per ordinary share based on an exchange rate of €1.00 = $1.0559 as published by the European Central Bank on October 19, 2023.

Abivax Announces the Pricing of its Initial Public Offering on the Nasdaq Global Market

PARIS, FRANCE / ACCESSWIRE / October 20, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today that trading of its ordinary shares on the regulated market of Euronext in Paris ("Euronext Paris") will be temporarily halted, at the Company's request, from the opening of the market at 9:00 a.m. CEST. This trading halt takes place in the context of the initial public offering of the Company's American Depositary Shares ("ADSs") on the Nasdaq Global Market (the "Global Offering"), in order to allow for the confirmation of allocations to investors and for the commencement of trading of the Company's ADSs on the Nasdaq Global Market.

Abivax Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris

Abivax S.A. ABVX, -2.53% has increased the size of its global offering to 20.33 million shares from 18.68 million shares as part of its uplisting to the Nasdaq under the ticker symbol “ABVX” from Euronext Paris, according to a filing late Wednesday.

Abivax increases size of Nasdaq uplisting deal

PARIS, FRANCE / ACCESSWIRE / October 18, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced the formal commencement of book-building and the filing of an amended registration statement on Form F-1, including an estimated initial public offering price range, in connection with its intention to issue, subject to market and other conditions, approximately 20,325,500 ordinary shares (including ordinary shares in the form of American Depositary Shares ("ADSs")) of the Company in an initial public offering of ADSs, each representing one ordinary share, in the United States (the "U.S. Offering") and a concurrent offering of ordinary shares in certain jurisdictions outside of the United States (the "European Private Placement", and together, the "Global Offering"). Abivax intends to grant the underwriters (the "Underwriters") a 30-day option to purchase additional ADSs and/or ordinary shares in an aggregate amount of up to 15% of the total number of ADSs and ordinary shares proposed to be sold in the Global Offering.

Abivax Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Price Range

Abivax has filed proposed terms to raise $250 million in an IPO to fund the development of its treatment candidates for chronic inflammatory diseases. The company's lead candidate, Obefazimod, is entering Phase 3 clinical trials for Ulcerative Colitis and Phase 2 trials for Crohn's Disease. The global market for treatments for ulcerative colitis is expected to reach $10.25 billion by the end of 2027, providing a significant opportunity for Abivax.

Abivax Readies $250 Million U.S. IPO For Drug Pipeline

PARIS, FRANCE / ACCESSWIRE / October 16, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced the start of its roadshow in connection with its intention to issue, subject to market and other conditions, 18,675,500 ordinary shares of the Company in an initial public offering of American Depositary Shares ("ADSs"), each representing one ordinary share, in the United States (the "U.S. Offering") and a concurrent offering of ordinary shares in certain jurisdictions outside of the United States (the "European Private Placement", and together, the "Global Offering"). Abivax intends to grant the underwriters a 30-day option to purchase additional ADSs and/or ordinary shares in an aggregate amount of up to 15% of the total number of ADSs and ordinary shares proposed to be sold in the Global Offering.

Abivax Announces the Start of the Roadshow for its Proposed Global Offering and Proposed Nasdaq Listing

Birkenstock Holding Plc

Agape ATP Corp

Global Mofy Metaverse Ltd

Gamer Pakistan Inc

La Rosa Holdings Corp

Primech Holdings Ltd

Perfect Moment Ltd

Five companies priced IPOs this week, led by Birkenstock's $1.5 billion offering. Three small issuers submitted initial filings. Birkenstock priced its IPO just below the midpoint to raise $1.5 billion at an $8.6 billion market cap, making it one of the largest consumer discretionary IPOs of the past two decades.

U.S. IPO Weekly Recap: Birkenstock Missteps In Public Debut

Abivax SA has filed for a $100 million IPO in the U.S. to raise funds for its pipeline development plans. The company's lead candidate, Obefazimod, is entering Phase 3 clinical trials for Ulcerative Colitis and Phase 2 trials for Crohn's Disease. The global market for treatments for ulcerative colitis is expected to exceed $10 billion by 2027, driving the growth of Abivax's products.

News for Abivax SA Stock (ABVX)